A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Clinical trial NCT05985915 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05985915
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-27
- Primary completion
- 2033-04-22
- Enrollment
- 612
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.